Tesamorelin Research: Visceral Fat and Liver-Fat Trials in HIV

Tesamorelin is a growth hormone-releasing hormone analogue studied in people with HIV and excess abdominal fat. Its research literature distinguishes fat surrounding internal organs from fat beneath the skin and from total body weight. That distinction is essential when interpreting claims about body composition: an improvement in one compartment does not establish the same effect in all the others. [1–3]

What the six-month liver-fat trial measured

A 2014 randomised, double-blind trial enrolled 50 people receiving antiretroviral treatment who had abdominal fat accumulation. It assessed visceral adipose tissue and liver fat over six months. The study found a greater reduction in visceral fat with tesamorelin than with placebo and a modest reduction in liver fat. [1]

The investigators also measured glucose. Fasting glucose increased relative to placebo early in follow-up, whereas the between-group change at six months was not statistically significant. The timing matters: a result described only at the final visit can obscure changes earlier in the study. This was a relatively small trial, and its authors called for further work on the clinical importance and longer-term consequences.

The 12-month study in people with HIV and fatty liver

A later multicentre trial enrolled 61 people with HIV and fatty liver; 60 received study treatment. Eligibility included a hepatic fat fraction of at least 5%. The primary outcome was change in that measurement over 12 months. Tesamorelin produced an estimated 4.1-percentage-point greater reduction than placebo, corresponding to a 37% relative reduction from baseline. [2]

Absolute and relative changes describe the same outcome differently. A 37% relative reduction does not mean that liver fat fell by 37 percentage points. At 12 months, 35% of the tesamorelin group and 4% of the placebo group had a hepatic fat fraction below 5%. Those findings concern a measured fat threshold; they are not a blanket declaration that every aspect of liver disease resolved.

Visceral fat and what happens after stopping

A separate placebo-controlled trial with an extension phase reported reduced visceral fat during tesamorelin treatment, without a corresponding reduction in abdominal subcutaneous fat. Participants who switched from tesamorelin to placebo lost the initial visceral-fat improvements. [3]

This makes duration and discontinuation part of the evidence, not minor details. A change maintained while participants receive a study medicine cannot automatically be described as permanent. It also explains why a body-composition result should not be rewritten as ordinary weight loss: different compartments and measurements may change in different ways.

Why the study population matters

These trials were conducted in defined HIV-related clinical settings. Extrapolation to people without HIV, athletes seeking changes in appearance or people with a different liver condition requires additional evidence. A shared interest in abdominal fat does not make those populations interchangeable.

The same caution applies when comparing tesamorelin with another peptide. Studies conducted in different populations, using different measurements and follow-up periods, cannot support a simple ranking based on the largest percentage reported. A direct comparison or a carefully justified evidence synthesis would be needed.

Safety and interpretation

Growth-hormone-related markers and glucose measures formed part of the clinical investigation. Reassuring results for a particular measurement over several months do not eliminate the need for clinical monitoring or establish safety in people excluded from the trials. These selected studies should be read alongside their eligibility criteria, adverse-event reports and follow-up limitations.

This evidence overview was prepared on 22 October 2026 and is not a treatment guide. Bali Peptide Lab sells laboratory research materials and has a commercial interest in this topic. Research-product specifications do not make a catalogue vial equivalent to a medicine used in a controlled trial, and the findings above do not justify personal administration of research materials.